Chronic rhinosinusitis with nasal polyposis (CRSwNP) is an umbrella term for a heterogeneous group of inflammatory disorders characterized by persistent polypoid inflammation of the sinonasal mucosa (≥12 weeks) and nasal obstruction.[@bib1] Symptoms are often severe and only partially responsive to treatment, and disease is commonly associated with difficult-to-treat asthma.[@bib1], [@bib2] There is an urgent unmet clinical need to understand the immunopathology of CRSwNP. Several studies have indicated regional variation in CRSwNP endotypes. Western countries show a predominance of eosinophilic T~H~2-associated polyps, and *Staphylococcus aureus* superantigens have been implicated in driving the T~H~2 response.[@bib3], [@bib4], [@bib5] Conversely, CRSwNP in patients from southern Asia is associated with neutrophilic infiltration and a local T~H~1/T~H~17 signature.[@bib3], [@bib4], [@bib6] Although potential sources of proeosinophilic cytokines in patients with CRSwNP include T cells, type 2 innate lymphoid cells (ILC2s), mast cells, and eosinophils, the local immune mechanisms regulating cytokine production remain poorly understood. Relatively little is also known of T-cell responses in the healthy nasal mucosa, although the local microenvironment appears to suppress T~H~2 responses.[@bib7]

Recently, the epithelial cell--derived cytokines IL-25 and IL-33, acting through their respective receptors IL-17RB and ST2, have been implicated in promoting T~H~2 responses in animal models of allergic inflammation.[@bib8], [@bib9], [@bib10] Expression of IL-17RB has been demonstrated on human peripheral blood T~H~2 cells differentiated *in vitro* by thymic stromal lymphopoietin--treated dendritic cells and on freshly isolated CD4^+^ T cells from patients with Churg-Strauss syndrome.[@bib11], [@bib12] IL-25 is also expressed within the bronchial mucosa of asthmatic patients and in the skin during allergen-induced late responses.[@bib11], [@bib13] Furthermore, ILC2s coexpress IL-17RB and ST2 and produce IL-5 and IL-13 in response to IL-25 and IL-33.[@bib14], [@bib15] ST2 is associated with T~H~2 immune responses in mice,[@bib16], [@bib17] and expression is increased in ILC2s and eosinophils from patients with CRSwNP.[@bib18], [@bib19], [@bib20] In human subjects baseline levels of IL-33 mRNA in epithelial cells derived from treatment-recalcitrant nasal polyps are increased compared with levels in cells derived from treatment-responsive nasal polyps.[@bib21] However, the local mucosal T-cell response in patients with CRSwNP and the potential interaction of T cells in the nasal mucosa with IL-25 or IL-33 have not been explored.

Therefore we hypothesized that the IL-25/IL-33 axis is involved in directing local mucosal T~H~2 responses in patients with eosinophilic CRSwNP. To test this hypothesis, we extensively phenotyped nasal T-cell responses from tissue explants of patients with CRSwNP and healthy control subjects.

Methods {#sec1}
=======

Detailed methods used in this study and reagent sources can be found in the [Methods](#appsec1){ref-type="sec"} section in this article\'s Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0010}. Clinical and demographic data for patients with CRSwNP and healthy volunteers are shown in [Table E1](#appsec1){ref-type="sec"} in this article\'s Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0015}.

Results {#sec2}
=======

Nasal polyp explant T cells are of an effector memory phenotype {#sec2.1}
---------------------------------------------------------------

The majority of donor-matched polyp- and peripheral blood--derived CD4^+^ and CD8^+^ T cells were determined to be αβ T cells. γδ T cells formed a minimal proportion of the T-cell population (see [Fig E1](#appsec1){ref-type="sec"} and [Table E2](#appsec1){ref-type="sec"} in this article\'s Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0020}). After short-term culture, both polyp and blood populations expressed high levels of CD45RO, which is consistent with a memory phenotype after restimulation. The majority of T cells in polyp cultures expressed significantly less CD62 ligand and CCR7 compared with blood T cells and displayed higher expression of CD49a, an integrin expressed by tissue-resident memory cells,[@bib22], [@bib23] suggesting that nasal polyp--derived T cells were predominately of an effector memory phenotype.[@bib24]

T~H~17 and T~H~2 cytokine profiles are detected in nasal polyps {#sec2.2}
---------------------------------------------------------------

Intracellular cytokine staining was performed on CD4^+^ T cells expanded from polyp explants and peripheral blood in parallel to establish the T~H~ cell cytokine profile. CD4^+^ T cells derived from polyps expressed significantly higher percentages of IL-17^+^ and IL-22^+^ cells together with T~H~2 cytokine (IL-5, IL-9, and IL-13)--producing cells ([Fig 1](#fig1){ref-type="fig"}, *A* and *B*), all of which showed negligible expression in expanded peripheral blood CD4^+^ T cells from the same donors. In addition, coexpression of IL-17 with IL-22 and IFN-γ was detected (see [Fig E2](#appsec1){ref-type="sec"} in this article\'s Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0025}). A significantly higher percentage of polyp T cells produced the proinflammatory cytokine TNF-α, although IFN-γ expression was equivalent in CD4^+^ T cells from both sources.

T~H~2 cytokine production is specific to CRSwNP, but T~H~17 cytokines are produced by nasal T cells from normal and inflamed tissue {#sec2.3}
-----------------------------------------------------------------------------------------------------------------------------------

We next examined whether this cytokine expression profile in polyp explants was disease or tissue specific. Therefore T-cell phenotypes were compared with those from nasal mucosal biopsy specimens from healthy volunteers. IL-17 was produced by a comparable percentage of T cells derived from healthy nasal and nasal polyp explants ([Fig 1](#fig1){ref-type="fig"}, *C*) and confirmed at the protein level in cell-culture supernatants. Minimal IL-13^+^ cells were observed in the healthy nasal mucosa ([Fig 1](#fig1){ref-type="fig"}, *C*). Although IL-4 expression was not examined by using flow cytometry, significantly increased IL-4 levels, in addition to IL-5 and IL-13 levels, were detected in the supernatants of polyp explant cultures compared with those seen in healthy nasal mucosa explants (see [Fig E3](#appsec1){ref-type="sec"} in this article\'s Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0030}).

IL-17RB is expressed by *in vitro* T~H~2-polarized but not T~H~1-polarized cells {#sec2.4}
--------------------------------------------------------------------------------

The IL-25 receptor IL-17RB is associated with T~H~2 cells and the promotion of T~H~2 responses.[@bib9], [@bib11] We sought to examine IL-17RB expression in homogenous human T~H~1/T~H~2 CD4^+^ populations differentiated from naive peripheral blood T cells, as previously described.[@bib25] Differentiated cells were highly polarized toward a T~H~1 (IFN-γ^+^, T-box transcription factor \[T-bet\]^+^, and IL-12 receptor β2 \[IL-12Rβ2\]^+^) or T~H~2 (IL-4^+^, IL-5^+^, GATA-3^+^, and chemoattractant receptor-homologous molecule expressed on T~H~2 cells \[CRTH2\]^+^) phenotype, and a significant increase in *IL17RB* gene expression was observed in T~H~2 versus T~H~1 cell lines ([Fig 2](#fig2){ref-type="fig"}, *A*). IL-17RB expression increased with time in *in vitro* T~H~2-polarized T-cell cultures only ([Fig 2](#fig2){ref-type="fig"}, *B* and *C*), which followed similar kinetics to type 2 cytokine production (data not shown). Furthermore, IL-17RB expression was correlated with IL-13 expression in T~H~2 cell cultures ([Fig 2](#fig2){ref-type="fig"}, *D*). Together, these data suggest IL-17RB to be a robust marker of human T~H~2 cells.

IL-17RB^+^ cells are a distinct T~H~2 cell population present in nasal polyps {#sec2.5}
-----------------------------------------------------------------------------

We next examined whether T-cell expression of IL-17RB is also a feature of target organ tissue CD4^+^ cells in eosinophilic polyps. A substantial proportion of polyp CD4^+^ T cells expressed IL-17RB, whereas negligible IL-17RB expression was observed in matched peripheral blood or healthy nasal mucosal specimens ([Fig 3](#fig3){ref-type="fig"}). Coexpression of IL-17RB with the T~H~2-associated prostaglandin D~2~ receptor CRTH2 ([Fig 3](#fig3){ref-type="fig"}, *B*) was also detected, but IL-17RB expression was negligible on T~H~17-associated CCR6^+^ or T~H~1-associated CXCR3^+^ cells. Consistent with the high frequency of IL-17^+^ cells, an abundance of CCR6-expressing cells was also found in both healthy nasal mucosa and polyp explants ([Fig 3](#fig3){ref-type="fig"}, *A* and *C*). CD8^+^ cells showed similar surface molecule expression patterns to CD4^+^ cells, although lower percentages of cells positive for the surface molecules examined were generally observed (see [Fig E4](#appsec1){ref-type="sec"} in this article\'s Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0035}).

Although short-term cultures were used to generate sufficient cell numbers for experimentation, flow cytometric analysis of polyp tissue T cells immediately after collagenase digestion confirmed IL-17RB expression was not a culture artifact (see [Fig E5](#appsec1){ref-type="sec"} in this article\'s Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0040}). Furthermore, percentages of T~H~2 and IL-17--producing cells were increased in digested polyp- versus blood-derived cells, which is consistent with findings from explant cultures.

IL-17RB^+^CD4^+^ cells derived from nasal polyp explants represent *in vivo* differentiated memory T~H~2 cells {#sec2.6}
--------------------------------------------------------------------------------------------------------------

To further address the phenotype of IL-17RB^+^CD4^+^ cells from nasal polyp explants, explant-derived cells were sorted by means of fluorescence-activated cell sorting for IL-17RB^+^CD4^+^ expression after short-term expansion. IL-17RB^−^CD4^+^ cells were also sorted for comparison. T~H~2-associated genes, including *IL4*, *IL5*, *IL9*, *IL13*, and *GATA3*, showed considerable upregulation in activated IL-17RB^+^CD4^+^ versus activated IL-17RB^−^CD4^+^ cells ([Fig 4](#fig4){ref-type="fig"}, *A*), with differential expression for a majority of these genes reaching statistical significance (see [Table E3](#appsec1){ref-type="sec"} in this article\'s Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0045}). Furthermore, correspondingly lower expression of T~H~1-associated genes, including *IFNG*, *LTA*, and *CCL3*, was identified. Moreover, the genes for promelanin-concentrating hormone and prostaglandin-endoperoxide synthase 2 were preferentially expressed in IL-17RB^+^ cells in line with data from *in vitro* polarized T~H~2 cultures ([Fig 2](#fig2){ref-type="fig"}, *A*) and previously published findings.[@bib26], [@bib27] Microarray-based gene expression results were confirmed by using quantitative RT-PCR analysis (see [Fig E6](#appsec1){ref-type="sec"} in this article\'s Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0050}).

IL-17RB^+^ cells predominantly and selectively produce T~H~2 cytokines {#sec2.7}
----------------------------------------------------------------------

We next examined whether IL-17RB expression colocalized with T~H~2 cytokines in nasal polyp explant T-cell cultures. [Fig 4](#fig4){ref-type="fig"}, *B*, shows the percentage of cells expressing IL-17RB when segregated by cytokine production. IL-5-producing, IL-13-producing, and IL-5/IL-13--coproducing cells were approximately 5 times more likely to coexpress IL-17RB compared with T~H~1/T~H~17 cytokine--producing cells (ie, 52% of IL-5--producing cells were IL-17RB^+^, whereas 8% of IFN-γ--producing cells were IL-17RB^+^). In addition, IL-17RB^+^ cells were accountable for the majority of IL-5/IL-13--coproducing T cells (59%; [Fig 4](#fig4){ref-type="fig"}, *B*). Notably, percentages of IFN-γ--and IL-17--producing cells were significantly lower in the IL-17RB^+^ population compared with those in the IL-17RB^−^ population. A similar trend was observed for TNF-α and IL-22.

The IL-33 receptor ST2 is also expressed by IL-17RB^+^ cells {#sec2.8}
------------------------------------------------------------

T cells from nasal polyp explants were next examined for mRNA expression of the IL-33 receptor ST2. Expression of transmembrane and soluble isoforms (sST2) of *ST2*, as measured by using quantitative RT-PCR, were increased in activated IL-17RB^+^ cells compared with IL-17RB^−^ cells ([Fig 4](#fig4){ref-type="fig"}, *C*), suggesting that IL-17RB^+^ T cells might also be IL-33 responsive.

IL-17RB and ST2 are functional and potentiate T~H~2 cytokine production by nasal polyp T cells {#sec2.9}
----------------------------------------------------------------------------------------------

T~H~2 cytokine expression was determined by means of flow cytometry in polyp explants cultured in the presence of recombinant human IL-25 or IL-33 to evaluate whether IL-17RB and ST2 expressed on polyp T cells were functional ([Fig 4](#fig4){ref-type="fig"}, *D*). Recombinant cytokines were added either on the day of explantation or day 7 after stimulation. Analysis was performed 7 days later. Addition of IL-25 induced a mean 1.5-fold increase in the percentage of IL-17RB^+^IL-5^+^CD4^+^ T cells and a 1.4-fold increase in the percentage of IL-17RB^+^IL-13^+^CD4^+^ T cells in explant cultures ([Fig 4](#fig4){ref-type="fig"}, *E*). Addition of IL-33 had a comparable effect to IL-25, with a mean 1.4-fold increase in the percentage of IL-17RB^+^IL-5^+^CD4^+^ T cells and a 1.2-fold increase in the percentage of IL-17RB^+^IL-13^+^CD4^+^ T cells. Time of recombinant cytokine addition had no effect on the response of IL-17RB^+^ST2^+^ cells. Addition of IL-25 to polyp-derived T cells at day 7 after stimulation was still associated with a significant increase in IL-17RB^+^IL-5^+^ and IL-17RB^+^IL-13^+^ CD4^+^ T-cell counts (data not shown).

Nasal polyp epithelium and eosinophils express IL-25 {#sec2.10}
----------------------------------------------------

Cellular sources of IL-25 within nasal polyp tissue were investigated by using immunohistochemistry. Immunostaining was observed in the epithelium of nasal polyps but not in healthy control biopsy tissue (see [Fig E7](#appsec1){ref-type="sec"}, *A*, in this article\'s Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0055}). Furthermore, a significantly higher number of IL-25^+^ cells were present in the polyp submucosa (see [Fig E7](#appsec1){ref-type="sec"}, *B*). These cells were identified to be eosinophils based on cell morphology (see [Fig E7](#appsec1){ref-type="sec"}, *C*). In contrast, immunoreactive IL-33 was detected in both nasal polyp and healthy biopsy tissue, with immunostaining indicating a predominantly epithelial and endothelial pattern of expression (see [Fig E8](#appsec1){ref-type="sec"} in this article\'s Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0060}).

IL-17RB^+^ and IL-17RB^−^ cells have distinct T-cell receptor specificities with common T-cell receptor clones exhibited by IL-17RB^+^ cells {#sec2.11}
--------------------------------------------------------------------------------------------------------------------------------------------

We next examined whether nasal IL-17RB^+^CD4^+^ T~H~2 cells in patients with CRSwNP represent oligoclonal populations driven by *in vivo* antigen or superantigen expansion. Clonality was examined by T-cell receptor variable β-chain (TCR Vβ) analysis with the immunoSEQ assay and compared in IL-17RB^+^CD4^+^ and IL-17RB^−^CD4^+^ cells sorted from nasal polyp explant cultures of 4 patients with CRSwNP. No skewing of TCR Vβ family use was observed (data not shown), but sequencing of complementarity-determining region 3 (CDR3) regions revealed that polyp IL-17RB^+^CD4^+^ cells contained a smaller number of unique clones compared with IL-17RB^−^CD4^+^ cells in all 4 cases analyzed ([Table I](#tbl1){ref-type="table"}). Additionally, less than 1% of sequenced clones were present within both IL-17RB^+^CD4^+^ and IL-17RB^−^CD4^+^ populations. Remarkably, 2 distinct common clones in IL-17RB^+^CD4^+^ T cells, identified to belong to the Vβ5.2 and Vβ6 families by using immunoSEQ analysis, were present in 3 of 4 patients with CRSwNP studied. Overall, these results suggest that polyp IL-17RB^+^CD4^+^ T cells have undergone clonal expansion and that common epitopes might drive this process, even in different patients.

T~H~17 cells are the default T~H~ cell phenotype in normal nasal mucosal immunity {#sec2.12}
---------------------------------------------------------------------------------

Given the abundant expression of IL-17 by CD4^+^ T cells derived from the healthy nasal mucosa in addition to nasal polyps, these cells were characterized further. In agreement with CCR6 and IL-17RB expression data ([Fig 3](#fig3){ref-type="fig"}), no coexpression of IL-17 and IL-13 was detected ([Fig 5](#fig5){ref-type="fig"}, *A*). In supernatants of CD3/CD28-stimulated T cells, IL-17 was produced by T cells derived from both healthy nasal mucosa and polyp tissue but not peripheral blood--derived T cells from the same patients ([Fig 5](#fig5){ref-type="fig"}, *B*).

CD4^+^ T-cell populations were also sorted from paired nasal explant and peripheral blood cultures for transcriptome profiling (see [Fig E9](#appsec1){ref-type="sec"} in this article\'s Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0065}). Preferential expression of T~H~17-associated genes was observed in activated nasal CD4^+^ cells. Of note, the 5 genes that were most highly overexpressed in nasal versus peripheral blood CD4^+^ T cells were all T~H~17 associated: *IL17F*, *IL22*, *CCL20*, *KLRB1* (CD161), and *IL1R1* (see [Table E4](#appsec1){ref-type="sec"} in this article\'s Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0070}). Significant overexpression of the gene for the DNA-sensing inflammasome component absent in melanoma 2 *(AIM2)* was also observed in nasal mucosal T cells. Analysis of additional selected T~H~17-associated genes further revealed preferential expression of *IL17A*, *IL21*, *IL23*, *IL23R*, aryl hydrocarbon receptor *(AHR)*, and *RORC* ([Fig 5](#fig5){ref-type="fig"}, *C*) by activated nasal CD4^+^ cells. These data suggest that the healthy, homeostatic T-cell response in the nasal mucosa is associated with a strong T~H~17 signature compared with the periphery.

T~H~17 cells in nasal polyps have a potentially protective immune homeostatic role associated with reduced IFN-γ coexpression {#sec2.13}
-----------------------------------------------------------------------------------------------------------------------------

T~H~17 cells can coproduce IFN-γ and IL-22. IL-17/IFN-γ double-positive cells have been associated with a pathogenic proinflammatory phenotype, whereas IL-17/IL-22 double-positive cells have been reported to have protective properties by inducing expression of antimicrobial peptides.[@bib28], [@bib29], [@bib30] Lower coexpression of IFN-γ by IL-17^+^ T cells from polyp explants was found compared with that seen in blood-derived cells ([Fig 5](#fig5){ref-type="fig"}, *D*). No difference was observed in the percentages of IL-17^+^ cells coexpressing IL-22.

Discussion {#sec3}
==========

Recently, ILC2s have been identified in nasal polyps,[@bib18], [@bib19], [@bib31] and the presence of T~H~2 cells in white patients with CRSwNP has been demonstrated.[@bib32] However, the local T-cell response itself remains relatively uncharacterized. Here, using a short-term explant model to expand and study T cells from surgical specimens, we report a significant population of IL-17RB--expressing T~H~2 cells in nasal polyps with a gene expression profile akin to that of highly polarized T~H~2 cells.[@bib25], [@bib26] Approximately 50% of IL-5^+^IL-13^+^ polyp-derived CD4^+^ T cells expressed IL-17RB, suggesting IL-17RB^+^ cells represent a subset of T~H~2 cells.

We demonstrate that IL-17RB^+^CD4^+^ cells from polyps express mRNA for both transmembrane and soluble isoforms of ST2 on activation and respond to both IL-25 and IL-33 with augmented IL-5 and IL-13 production. ST2 expression by *in vitro* differentiated human peripheral blood T~H~2 cells has been described,[@bib33] and both IL-25 and IL-33 receptors are expressed and functional on human and murine ILC2s.[@bib14], [@bib18], [@bib19], [@bib34] However, the role of these pathways in human mucosal T-cell responses has not been examined. These data now establish a direct link of IL-25, IL-33, and T~H~2 cells in human disease and suggest that IL-17RB^+^ST2^+^ T~H~2 cells likely contribute to CRSwNP pathogenesis through the IL-25/IL-33 axis. We found increased IL-25 immunostaining in polyps, localizing to eosinophils and epithelial cells, which is consistent with previously published reports[@bib11], [@bib12], [@bib13] and in agreement with the increased IL-25 mRNA expression seen in patients with eosinophilic CRSwNP reported by Iinuma et al.[@bib35] In addition, constitutive expression of IL-33 was detected in epithelium and endothelium of both healthy and polyp nasal tissue, which is in line with mRNA expression studies.[@bib31], [@bib36], [@bib37] These findings suggest that these cells might be endogenous sources of IL-25 and IL-33 in nasal polyps. However, the mechanism of IL-33 release is yet to be elucidated.

Colonization with *S aureus* in nasal polyposis is associated with high levels of IgE,[@bib38] and *S aureus* superantigens, such as staphylococcal enterotoxin B, can drive the T~H~2-type response in eosinophilic polyps.[@bib5], [@bib39] Here we demonstrate that nonrandom segregation of unique CDR3 clones occurs with 2 CDR3 clones present in the IL-17RB^+^ population in 3 of 4 samples analyzed. Although these results require confirmation in a larger study, they are suggestive of oligoclonality in the TCR Vβ repertoire within the IL-17RB^+^ polyp T-cell population and indicate possible expansion by common antigens in different patients. Routine skin prick testing in these patients with CRSwNP did not identify coincidental sensitization to a common aeroallergen (data not shown). Furthermore, the Vβ5.2 and Vβ6 families are reported to be preferentially expressed by cutaneous lymphocyte--associated antigen--positive cells responding to the superantigen staphylococcal enterotoxin A in patients with atopic dermatitis and induced by the toxic shock syndrome toxin 1 superantigen, respectively.[@bib40], [@bib41] Although speculative, this raises the possibility that local IL-17RB^+^ T~H~2 cells in patients with CRSwNP undergo antigen-specific expansion in response to common but as yet undefined epitopes with an additional non--antigen-specific component mediated by superantigens.

We demonstrate that the T~H~ response in the healthy nasal mucosa is heavily biased toward T~H~17 responses compared with the periphery. Although we did not examine the relative dominance of the T~H~17 phenotype compared with other T~H~ cell phenotypes, we observed that the 5 most overexpressed genes in normal nasal mucosal T cells compared with peripheral blood T cells were all strongly T~H~17 associated. We propose that a significant population of nasal T cells differentiate into T~H~17 cells *in vivo*, with the propensity to produce IL-17 and related cytokines should they become activated *in vivo*.[@bib42] We hypothesize that this T~H~17 phenotype represents a key part of the nasal mucosal host defense response. Priming of autologous monocytes with pathogens, such as *S aureus* and *Candida albicans*, induces T~H~17 responses in naive human T cells,[@bib43] suggesting that chronic exposure of the nasal mucosa to nonpathogenic and pathogenic microorganisms, such as *Staphylococcus epidermidis*, *S aureus*, and corynebacteria, could be the mechanism behind this response.

Within the T cells derived from healthy nasal tissue, we found that transcripts encoding IL-17F and IL-22 were the most highly upregulated. IL-17A and IL-17F are homologous molecules sharing 55% amino acid identity.[@bib44] Both induce expression of numerous chemokines, cytokines, and adhesion molecules, although IL-17A is more effective at inducing inflammatory gene expression.[@bib28], [@bib45], [@bib46], [@bib47] IL-17F is expressed by a wide variety of tissue, including in the lung,[@bib47], [@bib48] and can also potentiate IL-22--induced expression of antimicrobial peptides.[@bib28] Thus the presence of T cells able to produce IL-17F and IL-22 is suggestive of a function for these cells in nasal mucosal immune homeostasis. Microarray analysis also identified overexpression of AIM2 mRNA in nasal explant CD4^+^ T cells. The AIM2 inflammasome is activated by intracellular pathogens, leading to caspase-1--dependent IL-1β secretion.[@bib49], [@bib50] Further studies will be needed to examine whether this innate pathway is functional in nasal T~H~17 cells.

Our study has some limitations. For example, memory T cells were phenotyped after short-term expansion. Therefore it is possible that a proportion of CD45RA^+^ peripheral blood T cells acquired CD45RO expression during culture and might have retained some of their baseline CD62 ligand and CCR7 expression characteristics. In addition, IL-17RB--expressing T cells were mainly characterized after *in vitro* expansion. Analysis of freshly isolated IL-17RB^+^ T cells from digested polyps was hampered by low cell numbers and lower IL-17RB expression, possibly reflecting the effects of enzymatic digestion, and therefore data were obtained from fewer cases. The IL-17RB mAb used in these studies did not prove suitable for immunohistochemical analysis, and further studies will be needed for *in vivo* expression analysis of IL-17RB. Finally, the effect of IL-25 and IL-33 stimulation on T~H~2 responses *in vitro* was modest, although the concentrations of recombinant IL-25 and IL-33 used in this study were similar to previously published reports.[@bib12], [@bib35]

Nonetheless, our data establish a biological link between IL-17RB expression and responsiveness to IL-25 in T~H~2 cells derived from polyps. Further optimized culture studies will be needed to characterize this response fully. Although 2 recent studies have reported the existence of IL-17RB^+^ cells in patients with CRSwNP,[@bib35], [@bib51] our findings represent the first direct colocalization of IL-17RB with T~H~2 cells.[@bib35]

In conclusion, we identify functional IL-17RB as a marker of local T~H~2 cells present in chronically inflamed nasal polyp tissue from patients with CRSwNP. Coexpression of ST2 by these cells, in addition to ILC2s, indicates that the IL-25/IL-17RB and IL-33/ST2 pathways could be attractive therapeutic targets. In addition, these data also provide novel insights into mechanisms of nasal immune homeostasis and suggest a role for T~H~17 cells in this process.Key messages•For the first time, we show that local IL-17RB^+^ T~H~2 cells in nasal polyps coexpress ST2 and that both receptors function, in response to their respective ligands IL-25 and IL-33, to potentiate T~H~2 cytokine production.•IL-17RB^+^ T~H~2 cells express common TCR clones, which is suggestive of recognition, clonal expansion, or both of T cells driven by a common antigen or antigens in patients with CRSwNP.•T~H~17 cells are present in the nasal mucosa as part of the normal homeostatic immune response.
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![Differential expression of T~H~2/T~H~17 cytokines by polyp- and normal nasal mucosa--derived CD4^+^ cells. **A,** Representative staining on paired CD4^+^ blood and polyp cells. **B,** Percentages of polyp versus blood CD4^+^ cells producing cytokines (Wilcoxon matched-pairs signed-rank test, n = 6-18). **C,** IL-17 and IL-13 histograms for CD4^+^ biopsy and polyp cells (n = 3). Each *row* indicates an individual subject. *Gray*, Resting; *red*, activated. *NM bx*, Healthy nasal mucosa biopsy specimen. \**P* \< .05, \*\**P* \< .01, and \*\*\**P* \< .001.](gr1){#fig1}

![IL-17RB is a marker of T~H~2 cells. **A,** Comparison of activated T~H~1 versus T~H~2 samples identified 292 differentially expressed genes. The heat map shows selected T~H~1/T~H~2-associated genes. **B,** Representative data for IL-17RB expression by CD4^+^ cells cultured with IL-2/T~H~1/T~H~2 differentiation conditions. **C,** Mean frequency of IL-17RB^+^ cells in culture over time (T~H~1/T~H~2, n = 7-11; rIL-2 alone, n = 3-6). **D,** Linear regression analysis of IL-17RB/IL-13 expression in T~H~2 conditions (n = 4). \**P* \< .05 and \*\*\**P* \< .001.](gr2){#fig2}

![IL-17RB is expressed exclusively by polyp CD4^+^ T cells. **A** and **B,** Representative staining for T-cell phenotypic markers by polyp, healthy nasal biopsy, and paired peripheral blood cells. **C,** Expression of phenotypic markers by CD4^+^ T cells derived from blood and nasal tissue of healthy volunteers (n = 7) or patients with CRSwNP (n = 11; Kruskal-Wallis test with Dunn multiple comparison test). \**P* \< .05, \*\**P* \< .01, and \*\*\**P* \< .001.](gr3){#fig3}

![Polyp-derived CD4^+^IL-17RB^+^ cells have a T~H~2 profile and respond to IL-25 and IL-33. **A,** Heat map of 42 differentially expressed genes in polyp IL-17RB^+^ versus IL-17RB^−^ cells (n = 3). **B,** Cytokine-producing cells coexpressing IL-17RB (n = 5-13). **C,** Transmembrane and soluble ST2 mRNA expression (n = 4; Mann-Whitney test). **D,** Representative staining for polyp CD4^+^ cells with or without IL-25/IL-33. **E,** IL-5^+^/IL-13^+^ cells coexpressing IL-17RB with or without IL-25/IL-33. *Open symbols*, Day 0 addition (n = 5); *solid symbols*, day 7 addition (n = 8). The Wilcoxon test was used. \**P* \< .05, \*\**P* \< .01, and \*\*\**P* \< .001.](gr4){#fig4}

![A T~H~17 signature characterizes CD4^+^ T cells of the healthy nasal mucosa. **A,** Representative IL-13/IL-17 staining in polyp and healthy nasal mucosa biopsy specimen *(NM bx)* CD4^+^ cells (n = 3). **B,** IL-17 expression in explant culture supernatants (n = 7, mean + SEM; Mann-Whitney test. **C,** Heat map of T~H~17 genes in NM bx versus blood CD4^+^ cells (n = 3). **D,** IL-17 coexpression with IFN-γ/IL-22 in blood versus polyp CD4^+^ cells (n = 6; Wilcoxon matched-pairs signed-rank test). \**P* \< .05.](gr5){#fig5}

###### 

TCR Vβ repertoire analysis of IL-17RB^+/−^ cells

  Patient ID                  HKP020   HKP023   HKP026   HKP036                             
  --------------------------- -------- -------- -------- -------- ------- --------- ------- --------
  Total clones (productive)   4,871    1,146    969      3,801    1,896   443,183   2,435   47,486
  Unique clones (no.)         33       91       28       97       55      6,475     113     1,759
  Shared clones               0        1        25       11                                 
  Common clones                                                                             
   CASSLNTGYEQYF              \+       −        \+       \+       \+      −         −       −
   CASSYPGEAFF                \+       −        \+       −        −       −         \+      −

Numbers of unique TCR clones present in sorted polyp-derived CD4^+^IL-17RB^+^ and CD4^+^IL-17RB^−^ populations analyzed by using the immunoSEQ assay are shown (n = 4 separate donors). Amino acid sequences represent CDR3 regions of 2 common clones identified within the IL-17RB^+^ population of at least 3 of the 4 donors.
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